Peripheral T-cell Lymphoma Pipeline Insight Report: 38+ Emerging Therapies and Treatment Outlook | DelveInsight
December 12, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Peripheral T-cell Lymphoma Pipeline Insight Report: 38+ Emerging Therapies and Treatment Outlook | DelveInsight Peripheral T-cell lymphoma (PTCL)...
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas
February 03, 2021 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
December 08, 2019 12:00 ET
|
Kura Oncology, Inc.
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients...
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
June 14, 2019 07:00 ET
|
Kura Oncology, Inc.
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an...
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
May 07, 2019 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
April 02, 2019 16:04 ET
|
Kura Oncology, Inc.
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – –...
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
March 05, 2019 07:30 ET
|
Kura Oncology, Inc.
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
January 03, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
December 02, 2018 12:00 ET
|
Kura Oncology, Inc.
– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90%...
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
September 26, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...